|14th August 2020||Earl W Brien||150,000||Exercise of derivative||$0.26||$39,000.00|
|7th August 2020||Steven A Kriegsman||3,000,000||Exercise of derivative||$0.26||$780,000.00|
|7th August 2020||Steven A Kriegsman||1,164,179||Payment by withholding||$0.67||$779,999.93|
|7th August 2020||Louis Ignarro||700,000||Exercise of derivative||$0.26||$182,000.00|
|7th August 2020||Louis Ignarro||271,642||Payment by withholding||$0.67||$182,000.14|
|7th August 2020||Joel K Caldwell||450,000||Exercise of derivative||$0.26||$117,000.00|
|7th August 2020||Joel K Caldwell||174,627||Payment by withholding||$0.67||$117,000.09|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
CytRx Corp. is a biopharmaceutical research and development company. It focuses on developing novel anti-cancer drug candidates. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.